Global Cancer Biomarkers Market to Surpass US$ 63,377.8 Million by 2030 - Coherent Market Insights

News provided by

Jul 04, 2022, 13:30 ET

SEATTLE, July 4, 2022 /PRNewswire/ -- According to Coherent Market Insights, the Global Cancer Biomarkers Market is estimated to be valued at US$ 21,643.9 million in 2022 and is expected to exhibit a CAGR of 14.4% during the forecast period (2022-2030).

Key Trends and Analysis of the Global Cancer Biomarkers Market:

Major players operating in market are focusing on carrying out research and development activities for developing biomarkers for early detection of cancer. For instance, on June 10, 2022, Curis, Inc., a biotechnology company focused on development of innovative therapeutics for treatment of cancer, announced the presentation of novel findings on biomarker development for IRAK4 inhibitor emavusertib, collaborative work from the University of Florida in primary CNS lymphoma (pCNSL), and clinical data from the TakeAim Leukemia and TakeAim Lymphoma studies at the 2022 European Hematology Association (EHA) Hybrid Congress that took place in Vienna, Austria virtually from 9 - 12 June 2022.

Request Sample Copy of this Report @ https://www.coherentmarketinsights.com/insight/request-sample/175

Key Market Takeaways:

Global cancer biomarkers market is expected to exhibit a CAGR of 14.4% during the forecast period due to the increasing prevalence of cancer. For instance, according to the data provided by the World Health Organization on February 2022, cancer is a leading cause of death worldwide, accounting for nearly 10 million deaths in 2020, or nearly one in six deaths

Among biomarker types, the Protein Biomarkers segment is expected to dominate the segment growth over the forecast period, owing to its extensive use in analyzing protein concentration in blood, tissue, urine, and other body fluids for early cancer detection. Market players are focusing on carrying out research and developments activities for developing protein biomarkers for the detection of cancer, which is expected to drive market growth. For instance, in June 2, 2022, InterVenn Biosciences, a clinical technology company leveraging glycoproteomics to transform the future of healthcare, announced new data showing that its new DAWN IO Melanoma test accurately assesses and classifies advanced melanoma patients as likely or unlikely to benefit from immune checkpoint inhibitor therapies: either pembrolizumab alone or ipilimumab in combination with nivolumab.

On the basis of cancer types, Breast Cancer is expected to dominate the segment growth over the forecast period, owing to its increasing prevalence. For instance, according to the National Cancer Institute, the most common type of cancer is breast cancer, with about 290,560 new cases expected in the U.S., in 2022.

Key players operating in the global cancer biomarkers market include bioMérieux, Inc., INOVIQ, Bio-Rad Laboratories, Inc., Abbott, Becton, Dickinson and Company, Merck KgaA, QIAGEN, Thermo Fisher Scientific Inc., CENTOGENE N.V., PerkinElmer Inc., and Siemens Healthcare Private Limited.

Request for Customization @ https://www.coherentmarketinsights.com/insight/request-customization/175

Detailed Segmentation:

Global Cancer Biomarkers Market, By Biomarker Type:

Protein Biomarkers
Genetic Biomarkers
Other Cancer Biomarkers

Global Cancer Biomarkers Market, By Cancer Type:

Breast Cancer
Lung Cancer
Prostate Cancer
Kidney Cancer
Liver Cancer
Other Cancers

Global Cancer Biomarkers Market, By End User:

Hospitals
Academic and Cancer Research Institutes
Ambulatory Surgical Centers
Cancer Diagnostic Laboratories

Global Cancer Biomarkers Market, By Region:

North America

By Country:

U.S.
Canada

Europe

By Country:

U.K.
Germany
Italy
France
Spain
Russia
Rest of Europe

Asia Pacific

By Country:

China
India
Japan
ASEAN
Australia
South Korea
Rest of Asia Pacific

Latin America

By Country:

Brazil
Mexico
Argentina
Rest of Latin America

Middle East & Africa

By Country:

GCC Countries
Israel
South Africa
Rest of Middle East & Africa

Buy this Complete Report Now @ https://www.coherentmarketinsights.com/insight/buy-now/175

Find related trending reports below:

Cancer Diagnostics Market, By Test Type (Tumor Biomarkers Tests (PSA Tests, CTC Tests, AFP Tests, CA-19 Tests, HER2 Tests, BRCA Tests, ALK Tests, CEA Tests, EGFR Mutation Tests, KRAS Mutation Tests, Others)), Imaging (Ultrasound, Mammography, MRI Scan, PET Scan, CT Scan, SPECT & Others), Biopsy (Needle Biopsy, Endoscopic Biopsy, Bone Marrow Biopsy, Others), Liquid Biopsy Immunohistochemistry In Situ Hybridization), By Cancer Type (Breast Cancer, Lung Cancer, Colorectal Cancer, Melanoma, Blood Cancers, Prostate Cancer, Ovarian Cancer, Stomach Cancer, Liver Cancer, Others), By End User (Hospital Associated Labs, Independent Diagnostic Laboratories, Diagnostic Imaging Centers, Cancer Research Institutes, Others), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East & Africa) - Size, Share, Outlook, and Opportunity Analysis, 2020 – 2027

Genomic Biomarker Market, by Indication (Oncology, Cardiovascular diseases, Neurological diseases, and Others), by End User (Hospitals, Diagnostic & Research Laboratories, and Others), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2021 – 2028

Blood Based Biomarker Market, By Type (Screening Biomarker, Diagnosis Biomarker, and Others), By Disease (Cancer, Neurological Disorders, and Others), By Application (Diagnostics, Drug Discovery, and Personalized Medicine), and By Region (North America, Latin America, Europe, Asia-Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2030

About Us:

Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having sales office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 57 countries worldwide. We create value for clients through our highly reliable and accurate reports. We are also committed in playing a leading role in offering insights in various sectors post-COVID-19 and continue to deliver measurable, sustainable results for our clients.

Contact Us:

Mr. Shah
Senior Client Partner – Business Development
Coherent Market Insights
Phone:
US: +1-206-701-6702
UK: +44-020-8133-4027
Japan: +81-050-5539-1737
India: +91-848-285-0837
Email: [email protected]
Website: https://www.coherentmarketinsights.com
Follow Us: LinkedIn | Twitter